Streetbeat News

Analyst Ratings

CODX

Co-Diagnostics (NASDAQ:CODX) reported Q3 2023 GAAP EPS of $(0.20), beating the analyst consensus estimate of $(0.29) by 31.03%. The company also reported quarterly sales of $2.46M, surpassing the analyst consensus estimate of $200.00K by 1.13K%. However, these figures represent a decrease from the same period last year.

Portfolio Pulse from saritha@benzinga.com

November 09, 2023 | 9:59 pm

BTCUSD

Benzinga has identified three potential catalysts that could boost Bitcoin's value: the approval of spot Bitcoin ETFs, the Bitcoin halving event, and the perception that Bitcoin is currently undervalued. The approval of spot Bitcoin ETFs would legitimize Bitcoin as an investable asset and could lead to a significant influx of institutional money into the cryptocurrency market. The Bitcoin halving event, expected in 2024, could decrease supply and drive prices higher if demand remains strong. The perception that Bitcoin is undervalued could lead to a reassessment of its true value and adjust its price accordingly.

Portfolio Pulse from Murtuza Merchant

November 09, 2023 | 9:56 pm

XLO

Xilio Therapeutics reported Q3 losses of $(0.61) per share, beating the analyst consensus estimate of $(0.81) by 24.69 percent. This represents a 15.28 percent increase over losses from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:53 pm

AGL

Truist Securities analyst Jailendra Singh has maintained a 'Buy' rating on Agilon Health (NYSE:AGL) but lowered the price target from $27 to $23.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:52 pm

ELDN

Eledon Pharma reported Q3 losses of $(0.35) per share, beating the analyst consensus estimate of $(0.50) by 30 percent. This represents a 52.05 percent increase over losses from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:52 pm

GDOT

Green Dot (NYSE:GDOT) reported Q3 adjusted earnings of $0.14 per share, missing the analyst consensus estimate of $0.21 by 33.33%. This is a 68.18% decrease from the same period last year. However, the company's adjusted sales of $348.57 million beat the analyst consensus estimate of $335.65 million, marking a 3.37% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:50 pm

VCEL

Truist Securities analyst Samuel Brodovsky maintains a 'Hold' rating on Vericel (NASDAQ:VCEL) and raises the price target from $33 to $39.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:50 pm

VOR

Vor Bio (NASDAQ:VOR) has presented updated clinical data from its Phase 1/2a study of trem-cel (VOR33) in patients with acute myeloid leukemia (AML). The data shows successful engraftment of trem-cel in all seven patients treated to date. The company also reported hematologic protection in three patients treated with multiple cycles of Mylotarg. Vor Bio's next steps include dose escalation of Mylotarg and providing treatment opportunities for trem-cel patients who become measurable residual disease positive or relapse.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:49 pm

MODG

Truist Securities analyst Michael Swartz has maintained a 'Buy' rating on Topgolf Callaway Brands (NYSE:MODG), but lowered the price target from $25 to $18.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:48 pm

SHLS

Truist Securities analyst Jordan Levy has maintained a 'Buy' rating on Shoals Technologies Gr (NASDAQ:SHLS), but lowered the price target from $25 to $23.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:47 pm